Feasibility indicators | All studies (1982–2020) | Early Group (1982–2006) | Middle Group (2011–2013) | Late Group (2018–2020) | ||||
---|---|---|---|---|---|---|---|---|
N = 600 | N = 200 | N = 200 | N = 200 | |||||
N | Percent (%) | N | Percent (%) | N | Percent (%) | N | Percent (%) | |
Recruitment | 428 | 71.3 | 134 | 67 | 141 | 70.5 | 153 | 76.5 |
Retention | 595 | 99.2 | 197 | 98.5 | 198 | 99 | 200 | 100 |
Acceptability | ||||||||
 Description of quantitative Measure | 192 | 32 | 43 | 21.5 | 58 | 29 | 91 | 45.5 |
 Quantitative outcome | 219 | 36.5 | 52 | 26 | 70 | 35 | 97 | 48.5 |
 Description of qualitative outcome | 143 | 23.8 | 29 | 14.5 | 42 | 21 | 72 | 36 |
 Qualitative outcome | 157 | 26.2 | 39 | 19.5 | 46 | 23 | 72 | 36 |
Attendance | ||||||||
 Description of measure | 109 | 18.2 | 31 | 15.5 | 35 | 17.5 | 43 | 21.5 |
 Outcome | 199 | 33.2 | 65 | 32.5 | 71 | 35.5 | 63 | 31.5 |
Compliance | ||||||||
 Description of measure | 162 | 27 | 41 | 20.5 | 52 | 26 | 69 | 34.5 |
 Outcome | 187 | 31.2 | 48 | 24 | 55 | 27.5 | 84 | 42 |
Cost | 23 | 3.8 | 8 | 4.0 | 5 | 2.5 | 10 | 5.0 |
Treatment fidelity | ||||||||
 Description of measure | 109 | 18.2 | 22 | 11 | 39 | 19.5 | 48 | 24 |
 Outcome | 85 | 14.2 | 21 | 10.5 | 24 | 12 | 40 | 20 |
Total outcomes reported | ||||||||
 1 | 65 | 13 | 24 | 12 | 29 | 14.5 | 12 | 6 |
 2 | 143 | 27 | 61 | 30.5 | 44 | 22 | 38 | 19 |
 3 | 168 | 29.2 | 65 | 32.5 | 56 | 28 | 47 | 23.5 |
 4 | 136 | 21.3 | 39 | 19.5 | 43 | 21.5 | 54 | 27 |
 5 | 58 | 6.5 | 7 | 3.5 | 20 | 10 | 31 | 15.5 |
 6 | 29 | 2.7 | 4 | 2 | 8 | 4 | 17 | 8.5 |
 7 | 1 | 0.3 | 0 | 0 | 0 | 0 | 1 | 0.5 |
Mentioned feasibility-related parameters in the purpose statement | 357 | 59.5 | 100 | 50 | 116 | 58 | 141 | 70.5 |
Cited a guideline/framework for the reporting of preliminary studies | 58 | 9.7 | 2 | 1 | 11 | 5.5 | 45 | 22.5 |
Conducted/reported statistical analyses related to preliminary efficacy | 561 | 93.5 | 186 | 93 | 192 | 96 | 183 | 91.5 |
Made any statements about preliminary efficacy in conclusion | 371 | 61.8 | 101 | 50.5 | 128 | 64 | 142 | 71 |
Made positive statements about preliminary efficacy in conclusion. | 298 | 49.7 | 90 | 45 | 99 | 49.5 | 109 | 54.5 |